Vitamin D signaling in calcium and bone homeostasis: A delicate balance

Carmeliet, Geert; Dermauw, Véronique; Bouillon, Roger

doi:10.1016/j.beem.2015.06.001

Cited by 126 publications

(78 citation statements)

References 69 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vitamin D deficiency is very common worldwide, especially in seniors and osteoporotic patients, who are at increased risk of fracture. In adults, from a histological point of view, severe vitamin D deficiency (<10 ng/ml) has been associated with osteomalacia, which, due to impaired mineralization, can hamper bone strength and neutralize or diminish the effectiveness of antiosteoporotic treatments [10]. Accumulated evidences indicate a threshold level range of serum 25(OH)D between 21 and 30 ng/ml (53 to 75 nmol/l) to be recommended in fragile seniors at high risk for falls and fracture [9][10][11], especially before commencing bone antiresorptive or anabolic therapy [1,12].…”

Section: Introductionmentioning

confidence: 99%

Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens

et al. 2017

View full text Add to dashboard Cite

Summary Rationale: Calcidiol can be employed to correct vitamin D deficiency. Main results: Calcidiol administered at daily and weekly regimens over a period of 3 months was able to successfully raise 25-hydroxyvitamin D levels without altering other markers related to bone and mineral metabolism. Significance: Calcidiol supplementation is effective and safe. Introduction The correction of vitamin D status is necessary to maintain an optimal mineral and skeletal homeostasis. Despite cholecalciferol (vitamin D 3 ) is the most commonly used drug for vitamin D supplementation, the more hydrophilic compound calcidiol (25-hydroxyvitamin D 3 ) can be employed at daily, weekly, and monthly regimens to reach in the short term the target levels of serum 25-hydroxyvitamin D [25(OH)D]. In the administration of different doses of calcidiol pharmacokinetic study (ADDI-D study), the efficacy and safety of daily and weekly dosages of calcidiol were tested. Methods A total of 87 Caucasian, community-dwelling, postmenopausal women, aged 55 years or older, with vitamin D inadequacy (serum 25(OH)D levels <30 ng/ml, with mean 25(OH)D below 20 ng/ml, namely 16.5 ± 7.5 ng/ml) were randomized to receive three different dosages of calcidiol: 20 μg/day, 40 μg/day, and 125 μg/week for 3 months. The attained level of serum 25(OH)D was selected as primary endpoint to assess efficacy, while other parameters of mineral metabolism, (serum calcium, parathyroid hormone, phosphate, FGF23, urinary calcium, and markers of bone turnover) were assessed as secondary endpoints to establish safety. Results In all the three groups, serum 25(OH)D values significantly and promptly rose and plateaued above the 30 ng/ml threshold remaining within safety interval after 14 days of treatment, with similar efficacy for the similar daily and weekly dose regimens. The different dosages were also equally effective in controlling secondary hyperparathyroidism. No significant changes in calcium and phosphate metabolism and in bone turnover markers were observed for any of the treatments, confirming the safety of this compound. Conclusions The results of this study demonstrate the shortand mid-term efficacy and safety on core parameters of mineral metabolism of different daily or weekly dosages of calcidiol when used to treat vitamin D inadequacy or deficiency in postmenopausal women. Further studies are needed to assess falls as primary outcome of calcidiol supplementation.

show abstract

Section: Introductionmentioning

confidence: 99%

Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It is estimated that vitamin D has a positive effect on the bone regeneration through its endocrine activity on the calcium homeostasis, thereby increasing the supply of Ca for fracture regeneration (Carmeliet et al, 2015).…”

Section: Resultsmentioning

confidence: 99%

Calcium and Vitamin D Supplementation in Elderly Patients with Hip Fractures

Veeramalla¹,

Kasturi²

2017

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

“…Walking pace (miles per hour (mph)) was included as a measure of physical activity [30]. Use of calcium supplements [31,32] and health status [33] (excellent/very good/good/fair/poor), were also included. Additionally, the use of estrogen [34] and other medications known to modify bone mineral density or fracture risk (statins [35], loop diuretics [36], thiazides [37], thyroid hormones [38]), and corticosteroids [39]) were included.…”

Section: Covariatesmentioning

confidence: 99%

Soluble CD14 and fracture risk

et al. 2015

View full text Add to dashboard Cite

Summary Soluble CD14 (sCD14) is an inflammatory marker associated with osteoclasts. Using Cox proportional hazards models, we found a positive association between plasma levels of sCD14 and risk of incident fracture among participants in the Cardiovascular Health Study. sCD14 may be useful in identifying those at risk for fracture. Introduction Soluble CD14, a proinflammatory cytokine, is primarily derived from macrophages/monocytes that can differentiate into osteoclasts. The purpose of this study was to examine the relationship between sCD14 levels and osteoporotic fractures. Methods In the Cardiovascular Health Study, 5462 men and women had sCD14 levels measured at baseline. Incident hip fractures (median follow-up time 12.5 years) and incident composite fractures (defined as the first hip, pelvis, humerus, or distal radius fracture, median follow-up 8.6 years) were identified from hospital discharge summaries and/or Medicare claims data. Cox proportional hazards models were used to model the association between sCD14 levels and time to incident hip or composite fracture, overall and as a function of race and gender.Results In unadjusted models, there was a positive association between sCD14 levels (per 1 standard deviation increase, i.e., 361.6 ng/mL) and incident hip (HR, 1.26; 95 % CI, 1.17, 1.36) and composite (HR, 1.20; 95 % CI, 1.12, 1.28) fractures. When models were fully adjusted for demographics, lifestyle factors, and medication use, these associations were no longer significant. However, in whites, the association of sCD14 levels with hip fractures remained significant in fully adjusted models (HR, 1.11; 95 % CI, 1.01-1.23). Associations of sCD14 levels with hip and composite fracture did not differ between men and women. Conclusions In this large cohort of community-dwelling older adults, higher sCD14 levels were associated with an increased risk of incident hip fractures in whites.

show abstract

Vitamin D signaling in calcium and bone homeostasis: A delicate balance

Cited by 126 publications

References 69 publications

Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens

Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens

Calcium and Vitamin D Supplementation in Elderly Patients with Hip Fractures

Soluble CD14 and fracture risk

Contact Info

Product

Resources

About